Image_2_B-Lymphocyte Phenotype Determines T-Lymphocyte Subset Differentiation in Autoimmune Diabetes.tiff
Previous studies indicate that B-lymphocytes play a key role activating diabetogenic T-lymphocytes during the development of autoimmune diabetes. Recently, two transgenic NOD mouse models were generated: the NOD-PerIg and the 116C-NOD mice. In NOD-PerIg mice, B-lymphocytes acquire an activated proliferative phenotype and support accelerated autoimmune diabetes development. In contrast, in 116C-NOD mice, B-lymphocytes display an anergic-like phenotype delaying autoimmune diabetes onset and decreasing disease incidence. The present study further evaluates the T- and B-lymphocyte phenotype in both models. In islet-infiltrating B-lymphocytes (IIBLs) from 116C-NOD mice, the expression of H2-Kd and H2-Ag7 is decreased, whereas that of BAFF, BAFF-R, and TACI is increased. In contrast, IIBLs from NOD-PerIg show an increase in CD86 and FAS expression. In addition, islet-infiltrating T-lymphocytes (IITLs) from NOD-PerIg mice exhibit an increase in PD-1 expression. Moreover, proliferation assays indicate a high capacity of B-lymphocytes from NOD-PerIg mice to secrete high amounts of cytokines and induce T-lymphocyte activation compared to 116C B-lymphocytes. This functional variability between 116C and PerIg B-lymphocytes ultimately results in differences in the ability to shape T-lymphocyte phenotype. These results support the role of B-lymphocytes as key regulators of T-lymphocytes in autoimmune diabetes and provide essential information on the phenotypic characteristics of the T- and B-lymphocytes involved in the autoimmune response in autoimmune diabetes.
History
References
- https://doi.org//10.1084/jem.184.5.2049
- https://doi.org//10.1093/intimm/9.8.1159
- https://doi.org//10.1084/jem.187.12.1985
- https://doi.org//10.2337/diab.46.6.941
- https://doi.org//10.1073/pnas.0709205105
- https://doi.org//10.2337/db08-0420
- https://doi.org//10.1172/JCI32405
- https://doi.org//10.4049/jimmunol.180.5.2863
- https://doi.org//10.4049/jimmunol.167.10.5535
- https://doi.org//10.1002/1521-4141(200212)32:12<3657::AID-IMMU3657>3.0.CO;2-E
- https://doi.org//10.4049/jimmunol.167.2.1081
- https://doi.org//10.1002/eji.201445376
- https://doi.org//10.2337/db15-1606
- https://doi.org//10.2337/diabetes.54.1.69
- https://doi.org//10.4049/jimmunol.178.10.6533
- https://doi.org//10.2337/db06-0428
- https://doi.org//10.4049/jimmunol.1202104
- https://doi.org//10.4049/jimmunol.166.5.3194
- https://doi.org//10.4049/jimmunol.174.2.827
- https://doi.org//10.3390/jcm5110098
- https://doi.org//10.4049/jimmunol.1701717
- https://doi.org//10.1111/cei.12672
- https://doi.org//10.1038/nri.2015.18
- https://doi.org//10.1038/ni.1659
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity